TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06566976

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise Intervention
Description: Aerobic and resistance exercise will be components of the prehabiliation and rehabilitation programs. Given the presence of PAD, a particular emphasis will be placed on volume of walking and improving walking performance.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise Intervention
Description: Aerobic and resistance exercise will be components of the prehabiliation and rehabilitation programs. Given the presence of PAD, a particular emphasis will be placed on volume of walking and improving walking performance.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise Intervention
Description: Aerobic and resistance exercise will be components of the prehabiliation and rehabilitation programs. Given the presence of PAD, a particular emphasis will be placed on volume of walking and improving walking performance.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: VAPAHCS Rehabilitation Core Components
Description: The prehabilitation and rehabilitation programs include all Core Components of rehabilitation as outlined in guidelines. The current clinical VAPAHCS program includes smoking cessation, nutrition, risk factor management and psychosocial counseling referrals as appropriate, and these services will be available for the current proposal.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: VAPAHCS Rehabilitation Core Components
Description: The prehabilitation and rehabilitation programs include all Core Components of rehabilitation as outlined in guidelines. The current clinical VAPAHCS program includes smoking cessation, nutrition, risk factor management and psychosocial counseling referrals as appropriate, and these services will be available for the current proposal.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: VAPAHCS Rehabilitation Core Components
Description: The prehabilitation and rehabilitation programs include all Core Components of rehabilitation as outlined in guidelines. The current clinical VAPAHCS program includes smoking cessation, nutrition, risk factor management and psychosocial counseling referrals as appropriate, and these services will be available for the current proposal.
Study: NCT03963960

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hemodialysis with low dialysate flow
Description: Hemodialysis with low dialysate flow

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional triweekly high-flow hemodialysis
Description: Conventional triweekly high-flow hemodialysis
Study: NCT06567600

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low-dose Gemcitabine and Cisplatin Chemotherapy plus PD-1/PD-L1Antibody
Description: Low-dose Gemcitabine and Cisplatin Chemotherapy:~Gemcitabine 500 mg/m2 Cisplatin 12.5 mg/m2 on day 1 and day 8 of each 21-day cycle for up to eight cycles~PD-1/PD-L1Antibody:~Pembrolizumab 200mg on day 1 of each 21-day cycle Durvalumab 1500 mg on day 1 of each 21-day cycle After completion of gemcitabine and cisplatin, 200mg of Pembrolizumab or 1500 mg of Durvalumab may administer once every 3 or 4 weeks until clinical or imaging (per RECIST v1.1) disease progression or until unacceptable toxicity, withdrawal of consent, or any other discontinuation criteria were met.
Study: NCT06568289

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lignocaine
Description: A perineal infiltration of a 5-ml of the drug (100 mg of lignocaine) in the margins of the episiotomy. Careful aspiration before and during injection of the product should be performed to prevent intravascular injection. The entire contents will then be injected slowly at several points of infiltration. All planes will be infiltrated (vagina, muscle, and skin) before episiotomy repair.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine
Description: A perineal infiltration of a 5-ml of the study drug (20 mg of Bupivacaine) in the margins of the episiotomy. Careful aspiration before and during injection of the product should be performed to prevent intravascular injection. The entire contents will then be injected slowly at several points of infiltration. All planes will be infiltrated (vagina, muscle, and skin) before episiotomy repair.
Study: NCT06135272

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Resin infiltration
Description: Icon Resin Infiltration as minimally invasive technique

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Resin modified glass ionomer varnish
Description: Resin modified glass ionomer varnish as minimally invasive technique

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Light cured giomer varnish
Description: Light cured giomer varnish as minimally invasive technique
Study: NCT05518058

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: device and exercises
Description: device and exercises

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: device and exercises
Description: device and exercises
Study: NCT06250660

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Strawberry Intervention
Description: This is an intervention based on the intake of strawberry, specifically the Fortuna variety. This intervention is based on the intake of 250 g of fresh strawberries per day for a month. The amount and duration of strawberry intake has been consulted in other studies carried out with strawberries.
Study: NCT04510558

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Stoma closure with non-resorbable mesh (ULTRAPRO Advanced Mesh, Ethicon, Johnson & Johnson) in the sublay position
Description: * Antibioprophylaxis using cefuroxime and metronidazole~* Standard disinfection and sterile draping~* Circular incision around the stoma using the scalpel blade~* Dissection around the stoma until entering the abdominal cavity~* Closure of the stoma using a linear stapler~* A midline laparotomy may be performed or not~* Realization of an extra-corporeal or intra-corporeal side-to-side handsewn anastomosis~* Closure of the posterior aponeurosis using separate Maxon 2-0 stitches~* Application of an ULTRAPRO Advanced Mesh, Ethicon, Johnson \& Johnson, with +2cm on the edges, secured by 4 stiches of Maxon 2-0~* Closure of the anterior aponeurosis using separate Maxon 2-0 stitches~* No subcutaneous stitches~* Partial purse string skin closure using Monocryl 3-0~* Standard wound dressing

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Stoma closure without mesh
Description: * Antibioprophylaxis using cefuroxime and metronidazole~* Standard disinfection and sterile draping~* Circular incision around the stoma using the scalpel blade~* Dissection around the stoma until entering the abdominal cavity~* Closure of the stoma using a linear stapler~* A midline laparotomy may be performed or not~* Realization of an extra-corporeal or intra-corporeal side-to-side handsewn anastomosis~* Closure of the posterior aponeurosis using separate Maxon 2-0 stitches~* Closure of the anterior aponeurosis using separate Maxon 2-0 stitches~* No subcutaneous stitches~* Partial purse string skin closure using Monocryl 3-0~* Standard wound dressing
Study: NCT06452017

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telerehabilitation exercise program
Description: 5 min warmup will include ankle plantar and dorsiflexion ,trunk side flexion ,shoulder circles ,shoulder ROMS.it will be followed by 5 min aerobics that includes spot marching and side stepping. it will be followed by resistance exercise which will be divided into 3 groups. each group of exercise will be performed one day each. chair squats, arm pulls, seated triceps, biceps curls etc. are included in these resistance exercises. intensity of each exercise will be progressively increased.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Routine medical care
Description: The control group will be given routine medical care (including dietary modification, oral anti diabetics (metformin) and advised to do regular walk (20-30min/day).
Study: NCT04937413

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Evolocumab
Description: Evolocumab subcutaneous injection
Study: NCT06483009

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cryoablation
Description: Cryoablation: For subjects assessed as stable disease (SD) after two cycles of medication, one session is performed under local anesthesia after assessment. The multidisciplinary team, including investigators and radiologists, evaluates the feasibility of tumor ablation based on the size, location, and proximity to major blood vessels. Criteria for eligible lesions include a maximum diameter \<5cm, relatively isolated lesion location, and not adjacent to major blood vessels or vital structures. Cryoablation is performed using a 17G IceRod Plus 1.5 cryoablation needle, guided by CT, and avoiding nearby anatomical structures using the Visual-ICE cryoablation system.
Study: NCT04241588

Intervention type: DEVICE
Intervention: 3D Printed Upper-limb Prosthesis
Description: The fingers and thumb were made of polylactic acid polymer manufactured using industrial 3D printers. The palm, socket, forearm brace, and leveraging the structure were made of polylactic acid which has properties similar to thermoplastic that facilitate post-manufacturing adjustments. Elastic cords placed inside the dorsal aspect of the fingers provided passive finger extension. Finger flexion was driven by non-elastic cords along the palmar surface of each finger and was activated through 20-30 degrees of wrist or elbow flexion. The device will be given to participants so that they may practice using the device at home.

Intervention type: OTHER
Intervention: Control
Description: A 3D printed hand with be fitted to simulate a prosthesis.
Study: NCT05234801

Intervention type: DEVICE
Intervention: DARCO™ Headed Cannulated Screw
Description: The DARCO™ Headed Cannulated Screw is a multi-size screw system designed to be used over a guide pin or wire with instrumentation to provide interfragmentary compression and stability for bone fracture/fragment fixation.

Intervention type: DEVICE
Intervention: ORTHOLOC™ 3Di Recon-Midfoot/Flatfoot System
Description: A multi-indication foot reconstruction solution providing indication specific implants and instruments designed to address the unique demands of the forefoot and midfoot.

Intervention type: DEVICE
Intervention: ORTHOLOCTM 3Di 2 Foot Reconstruction System: CROSSCHECK™ Module
Description: A comprehensive fixation system consisting of a wide variety of plate options, created with the purpose of stabilization and fixation of fractures, revision procedures, joint fusion and reconstruction of small bones of the feet.
Study: NCT05255731

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Low frequency laser activated photobiomodulation
Description: Protocol description Infrared: analgesia, biostimulation of tissues, edema and hyperemia (hard and soft tissues). There will be 11 laser application points, 3 intra-oral and 8 extra-oral, with a total dose of 33J.~Intraoral: one point in the region of the mandibular lingula (point of submersion of the mandibular nerve), one vestibular point and one lingual point in relation to the alveolus of the extracted wisdom tooth.~Extraoral: for muscle relaxation, five points on the masseter muscle; for oedema drainage, one point in each lymph node region: parotid, submandibular and buccal.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Low frequency laser photobiomodulation inactive
Description: The same protocol as the activated group
Study: NCT06389578

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Teprotumumab
Description: SC administration and IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Teprotumumab
Description: SC administration and IV infusion
Study: NCT05503186

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Text Message
Description: The intervention consists of a series of text messages aimed to facilitate secure storage and disposal of unused opioid medications.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Information provided by the physician and/or pharmacist.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard of Care
Description: Information provided by the physician and/or pharmacist.
Study: NCT05932797

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Multimodal intervention in Long Covid19
Description: The intervention will consist of physical, psychological, cognitive and nutritional training and treatment to be carried out at the Teaching and Research Assistance Center of the University of Magellanus (CADI UMAG), program includes 12 sessions of cognitive behavioral therapy sessions, 12 kinesic rehabilitation sessions, 12 treatment sessions per nutrition professional, 12 rehabilitation sessions with occupational therapy professional and 12 rehabilitation sessions with a speech therapist.
Study: NCT06063694

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Synthetic electrospun fiber matrix
Description: Electrospun fiber matrices have long been investigated as an innovative construct for use in tissue engineering and regenerative medicine research due to their ability to mimic the structure and scale of native tissue. Clinical studies have demonstrated clinical efficacy in treating both chronic and acute wounds. There is strong evidence to support the application of a synthetic electrospun fiber matrix will generate favorable wound healing and reduce infection rates when used to augment transmetatarsal amputation.
Study: NCT04870905

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tis-U-Sol
Description: Tislelizumab 200mg will be given every 3 weeks for 12 cycles
Study: NCT05380063

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: De-escalated Dual Antiplatelet Therapy
Description: ticagrelor (90mg twice daily) + aspirin (100 mg once daily) during first 3 months post CABG, then switching to aspirin (100 mg once daily) + placebo (twice daily) for 9 months.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dual Antiplatelet Therapy
Description: Ticagrelor (90mg twice daily) + aspirin (100 mg once daily) for 1 year post CABG.
Study: NCT06060847

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Liver resection and simultaneous sleeve gastrectomy for HCC induced by metabolic syndrome
Description: Patients in the experimental arm will undergo liver resection for HCC and sleeve gastrectomy for MS during the same surgical procedure.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Liver resection for HCC induced by metabolic syndrome
Description: Patients in the active comparator arm will undergo liver resection for HCC
Study: NCT06439524

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 40 mg relugolix, 1 mg estradiol, 0.5 mg norethindrone acetate
Description: if randomized to study drug, participants will take one tablet Rel-CT daily following excisional surgery for endometriosis
Study: NCT04948138

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Glutamine oral supplementation
Description: Oral supplementation with 10-15 g/day of glutamine (adjusted for weight and plasma concentrations).
Study: NCT04894617

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amantadine
Description: 200 mg Amantadine daily for a total of 5 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Lactose monohydrate
Description: Lactose monohydrate two tablet daily for a total of 5 days.
Study: NCT05599035

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: repititive transcranial magnetic stimulation
Description: a figure-of-8 coil (7-cm diameter loop) positioned over the parietal area for ten sessions (10 trains, with frequency of stimulation 20-Hz, each lasting for 10 seconds with an inter-train interval of 30 seconds. The intensity of stimulation was set at 80% of the RMT for the first dorsal interosseous (FDI) of the contralateral hand with a total 2000 pulses for each parietal area.)

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: repititive transcranial magnetic stimulation
Description: a figure-of-8 coil (7-cm diameter loop) positioned over the parietal area for ten sessions (10 trains, with frequency of stimulation 20-Hz, each lasting for 10 seconds with an inter-train interval of 30 seconds. The intensity of stimulation was set at 80% of the RMT for the first dorsal interosseous (FDI) of the contralateral hand with a total 2000 pulses for each parietal area.)
Study: NCT05018572

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: I AM
Description: I am has a biopsychosocial perspective with a focus on pain management in migraines. The cognitive behavioural interventions being tested are Mindfulness, Acceptance and Commitment Therapy (ACT), Compassion Focused Therapy and Physiotherapist-led cardiotherapy. The treatment program consists of ten modules of texts, animated films with a fictional person to identify with, recorded audio exercises adapted for patients with migraines and filmed physiotherapeutic exercises with physiotherapists.The interventions in I am are personalised in that the first three modules and module 10 are for those who are being helped by a shorter treatment. The other modules, four to ten, are a more in-depth treatment for those who have frequent or chronic migraines. The participants are in contact with processors via message function as well as via phone at startup, at the middle of treatment and termination. The duration of treatment is 4-10 weeks.
Study: NCT04978792

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online self-compassion intervention
Description: An online self-guided intervention that uses widely available exercises and information.
Study: NCT06584786

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Jing Si herbal tea (JSHT)
Description: JSHT has been approved by the Ministry of Health and Welfare of Taiwan (registration number MOHW-PM-060635).

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Jing Si herbal tea (JSHT)
Description: JSHT has been approved by the Ministry of Health and Welfare of Taiwan (registration number MOHW-PM-060635).

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo of JSHT

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo of JSHT
Study: NCT04978792

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Active Control
Description: Participants will complete written exercises and breathing exercises that are not associated with self-compassion
Study: NCT06048484

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic body radiotherapy (SBRT)
Description: SBRT 40 gray (Gy) over 5 fractions

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Stereotactic body radiotherapy (SBRT)
Description: SBRT 40 gray (Gy) over 5 fractions
Study: NCT06367439

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual reality exercise condition
Description: Participants will complete a virtual reality exercise (i.e., Supernatural) tutorial (YouTube instruction and in-headset gameplay instruction/practice) and will complete a 18-20 minute affect measurement medium intensity virtual reality exercise (i.e., Supernatural) session in the Behavioural Medicine Lab (UVic).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual reality exercise condition
Description: Participants will be provided a virtual reality headset (Meta Quest 3 Headset) and subscription to a virtual reality exercise game (i.e., Supernatural) for 10 weeks. Participants will be instructed to participate in 75 minutes of medium intensity Supernatural physical activity (equivalent to 75 minutes of vigorous physical activity) per week in their own home.
Study: NCT06048484

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic body radiotherapy (SBRT)
Description: SBRT 40 gray (Gy) over 5 fractions
Study: NCT05019872

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: (Components of) pasta meal
Description: Samples will be provided one by one in cups labeled with an unique code.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: (Components of) pasta meal
Description: Samples will be provided one by one in cups labeled with an unique code.
Study: NCT06117436

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cilostazol
Description: Cilostazol 100 MG oral tablet once daily antiplatelet, Selenium 200mcg tablet once daily, anti oxidant

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cilostazol
Description: Cilostazol 100 MG oral tablet once daily antiplatelet, Selenium 200mcg tablet once daily, anti oxidant

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Selenium
Description: Selenium 200 mcg oral tablet once daily
Study: NCT06048484

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic body radiotherapy (SBRT)
Description: SBRT 40 gray (Gy) over 5 fractions

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zimberelimab
Description: 240 mg intravenously (IV)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zimberelimab
Description: 240 mg intravenously (IV)
Study: NCT05019872

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: (Components of) pasta meal
Description: Samples will be provided one by one in cups labeled with an unique code.
Study: NCT06048484

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zimberelimab
Description: 240 mg intravenously (IV)
Study: NCT05019872

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: (Components of) pasta meal
Description: Samples will be provided one by one in cups labeled with an unique code.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: (Components of) pasta meal
Description: Samples will be provided one by one in cups labeled with an unique code.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: (Components of) pasta meal
Description: Samples will be provided one by one in cups labeled with an unique code.